AzurRx BioPharma Inc (NASDAQ:AZRX) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Brokerages have set a one year consensus target price of $8.25 for the company and are forecasting that the company will post ($0.23) earnings per share for the current quarter, according to Zacks. Zacks has also given AzurRx BioPharma an industry rank of 179 out of 265 based on the ratings given to its competitors.
Separately, HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of AzurRx BioPharma in a research report on Thursday, September 28th.
AzurRx BioPharma (NASDAQ:AZRX) traded down $0.07 during mid-day trading on Friday, reaching $3.34. 28,543 shares of the company were exchanged, compared to its average volume of 64,151. AzurRx BioPharma has a one year low of $2.40 and a one year high of $5.25.
AzurRx BioPharma (NASDAQ:AZRX) last posted its quarterly earnings results on Monday, November 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.13). analysts anticipate that AzurRx BioPharma will post -1.05 earnings per share for the current fiscal year.
About AzurRx BioPharma
AzurRx BioPharma, Inc is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.